NSE: STAR | BSE: 532531

Strong Performer

Download real time

878.05 -13.90 (-1.56%)

71.14% Gain from 52W Low

88,552 NSE+BSE Volume

NSE 17 Mar, 2026 11:25 AM (IST)

8,093.2

Market Cap

High in industry

Beta 1Year

Average volatility

Strides Pharma Science Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for STAR, BSE:532531 Strides Pharma Science Ltd.

Strides Pharma Science Ltd.

14 Aug 2017

878.05

-1.56%

Strides Shasun Ltd Q1FY18 results comment

Results Update: Strides Pharma Science Ltd.

HDFC Securities

Revenue decreased by 5.25% to Rs. 841.77 Cr in Q1FY18 when compared to the previous quarter. Revenue decreased by 5.25% to Rs. 841.77 Cr in Q1FY18 when compared to the previous quarter.

Strides Pharma has gained 49.44% in the last 1 Year

Strides Pharma Science Ltd.

29 May 2017

878.05

-1.56%

Result Update:Strides Shasun

Buy: Strides Pharma Science Ltd.

Axis Direct

Strides reported Q4'17 EBITDA of Rs 1.56bn, 28% below our expectations, hit by challenging environment across key markets. EBITDA including other income was Rs 2.1 bn, which is ~95% of H2'17 EBITDA guidance.

Promoters unpledged 13.53% of shares in last quarter. Total pledge stands at 30.60% of promoter holdings

Strides Pharma Science Ltd.

26 May 2017

878.05

-1.56%

Strides Shasun Ltd Q4FY17 results comment

Results Update: Strides Pharma Science Ltd.

HDFC Securities

Revenue fell by 8.86% to Rs. 522.8 Cr in Q4FY17 when compared to the previous quarter.

Number of FII/FPI investors increased from 275 to 289 in Dec 2025 qtr.

Strides Pharma Science Ltd.

06 Feb 2017

878.05

-1.56%

Strides Shasun Ltd Q3FY17 results comment

Results Update: Strides Pharma Science Ltd.

HDFC Securities

Revenue decreased by 4.98% to Rs. 876.29 Cr in Q3FY17 when compared to the previous quarter. On the other hand, it grew by 5.11% when compared with Q3FY16.

Promoters unpledged 13.53% of shares in last quarter. Total pledge stands at 30.60% of promoter holdings

Strides Pharma Science Ltd.

17 May 2016, 12:00AM

878.05

-1.56%

Strides Shasun Limited

Strides Pharma Science Ltd.

ICICI Securities Limited

Q4FY16 consolidated revenues grew 43% YoY to | 1002 crore due to 115% growth in regulated markets (34% of revenues) and 102% growth in the institutional business (19% of revenues). On the other hand, PSAI...

Number of FII/FPI investors increased from 275 to 289 in Dec 2025 qtr.

Strides Pharma Science Ltd.

27 Oct 2015

878.05

-1.56%

Strides Arcolab - 2QFY16 Result Update

Buy: Strides Pharma Science Ltd.

Reliance Securities

Margins in line, higher other income beats profits Strides' 2QFY16 result was in-line on the operating front at 13.1%; however, higher other income led to 20% beat in profitability. The regulated market (including 1 month of Arrow sales) remained the pioneer of growth led by ramp up in new products. Management has guided for sales of Rs18-20bn and EBITDA of Rs3.53.8bn in 2HFY16E. We remain optimistic on company's business prospects in India, Africa and the US. Besides, its merger with Shasun and integration of Arrow Pharma will help create significant value over medium term, as operational synergies play out. Focus on increasing profitability and reduction in debt remains...

Strides Pharma Science Ltd.'s price crossed below 50Day SMA today

Strides Pharma Science Ltd.

28 May 2015

878.05

-1.56%

Strides Arcolab Limited

Strides Pharma Science Ltd.

ICICI Securities Limited

Strides Pharma Science Ltd.'s price crossed below 50Day SMA today

Strides Pharma Science Ltd.

31 Mar 2015

878.05

-1.56%

Strides Arcolab Ltd.

Buy: Strides Pharma Science Ltd.

Ashika Research

operational flexibility. It has a diversified product portfolio with 300+ products including nutraceuticals, Rx soft gelatin capsules, sachets and oral solids in wide ranging therapies. Strides has 8...

Promoters unpledged 13.53% of shares in last quarter. Total pledge stands at 30.60% of promoter holdings

Is Strides Pharma Science Ltd. worth buying?

492 Votes:

Buy 78.86%

Sell 11.79%

Hold 9.35%

RESEARCH REPORTS

Accumulate SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf